Acadia Pharmaceuticals (ACAD) reported Q1 earnings late Wednesday of $0.02 per diluted share, down from $0.11 a year earlier.

Analysts polled by FactSet expected $0.05.

Revenue for the quarter ended March 31 was $268.1 million, compared with $244.3 million a year earlier.

Analysts surveyed by FactSet expected $280.3 million.

For 2026, the company continues to expect revenue of $1.22 billion to $1.28 billion. Analysts expect $1.24 billion.

Acadia Pharmaceuticals shares were down 2.9% in premarket activity Thursday.